• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

    2/14/23 8:14:00 AM ET
    $APEN
    Industrial Specialties
    Health Care
    Get the next $APEN alert in real time by email
    SC 13G/A 1 d439068dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    APOLLO ENDOSURGERY, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    03767D108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 03767D108

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Master Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      FI


    CUSIP NO. 03767D108

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP NO. 03767D108

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Group, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP NO. 03767D108

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Guy Levy

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    Item 1.

     

    (a)    Name of Issuer
       Apollo Endosurgery, Inc.
    (b)    Address of Issuer’s Principal Executive Offices
      

    1120 S. Capital of Texas Highway

    Building 1, Suite #300

    Austin, TX 78746

    Item 2.

     

    (a)    Name of Person(s) Filing
      

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

    (b)    Address of Principal Business Office or, if none, Residence
      

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    (c)    Citizenship
      

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC - Delaware

    Guy Levy – United States

    (d)    Title of Class of Securities
       Common Stock


    (e)    CUSIP Number
       03767D108

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Item 4. Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

    As of the close of business on December 31, 2022, the Reporting Persons did not beneficially own any shares of the common stock of the Issuer.

    Item 5. Ownership of Five Percent or Less of a Class

    Not applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.


    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023     Soleus Capital Master Fund, L.P.
        By:   Soleus Capital, LLC, its General Partner
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023     Soleus Capital, LLC
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023     Soleus Capital Group, LLC
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023    

    /s/ Guy Levy

        Name: Guy Levy

     

    Footnotes:   
    Attention:    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
    Get the next $APEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APEN

    DatePrice TargetRatingAnalyst
    1/4/2023$10.00Buy → Hold
    Stifel
    11/30/2022$14.00 → $10.00Buy → Hold
    Lake Street
    2/23/2022$12.00 → $10.00Buy
    Stifel
    12/15/2021$13.00Outperform
    Cowen & Co.
    12/9/2021$12.00Buy
    Stifel
    9/9/2021$15.00Overweight
    Stephens
    More analyst ratings

    $APEN
    Financials

    Live finance-specific insights

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

      AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi

      10/18/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

      AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op

      7/21/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mcgaughy R Kent Jr

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:15:52 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Cpmg Inc

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:13:25 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Barr John R

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 7:56:41 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Leadership Updates

    Live Leadership Updates

    See more
    • MIMEDX Announces Leadership Transition

      K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w

      9/6/22 7:00:00 AM ET
      $APEN
      $MDXG
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors

      Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi

      4/4/22 7:15:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

      Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A

      1/18/22 7:45:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity

      MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA

      12/13/22 7:30:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to be Acquired by Boston Scientific

      Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price

      11/29/22 7:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apollo Endosurgery Inc.

      15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/14/23 10:24:35 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:16 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Endosurgery downgraded by Stifel with a new price target

      Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00

      1/4/23 7:13:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery downgraded by Lake Street with a new price target

      Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously

      11/30/22 9:24:28 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Stifel reiterated coverage on Apollo Endosurgery with a new price target

      Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      2/23/22 8:47:05 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      5/8/23 11:07:57 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 8:50:48 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Apollo Endosurgery Inc.

      SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 4:00:12 PM ET
      $APEN
      Industrial Specialties
      Health Care